Sudarshan Pharma Industries Annual Report

Fund RaiseAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Fund RaiseAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

Financial ResultsAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sudarshan Pharma Industries Q2 FY27 Results: Net Profit ₹8.1 Cr, Up 92.9% YoY

Sudarshan Pharma Industries Ltd reported revenue from operations of ₹217 Cr (+28.5% YoY) and net profit of ₹8.1 Cr (+92.9% YoY) for Q2 FY27.

Key figure

Net profit ₹8.1 Cr · +92.9% YoY

Board Meeting DateAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sudarshan Pharma Industries Board Meeting Date

Sudarshan Pharma's board meets 29 October 2026 to consider Q2 results and a fund-raising proposal. Trading window remains closed until 48 hours after results.

SME to Main Board MigrationAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sudarshan Pharma Industries SME to Main Board Migration

Sudarshan Pharma's shares will list on NSE's main board from October 27, 2026, migrating from BSE SME. Trading begins under symbol SUDARSHAN, marking a platform upgrade.

Other Announcement

Sudarshan Pharma Industries Other Announcement

Sudarshan Pharma Industries Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.

Annual ReportVineet Laboratories Ltd VINEETLAB

Vineet Laboratories Annual Report

Vineet Laboratories filed its FY 2025-26 Annual Report, which marks its turnaround and recapitalisation year. The AGM is scheduled for 30 November 2026.

Annual ReportIndrayani Biotech Ltd INDRANIB

Indrayani Biotech Annual Report

Indrayani Biotech has filed its 34th Annual Report for FY2025-26, containing the AGM notice for 30 November 2026 by VC/OAVM. The chairman notes a Rights Issue was initiated in October 2026 to raise capital.

Annual ReportESDS Software Solution Ltd ESDS

ESDS Software Solution Annual Report

ESDS Software Solution submitted its FY2025-26 Annual Report along with the AGM notice. The AGM is on 30 November 2026 via VC/OAVM, with remote e-voting.

Annual ReportThe Orissa Minerals Development Company Ltd ORISSAMINE

The Orissa Minerals Development Company Annual Report

Orissa Minerals Development Company filed its FY 2025-26 Annual Report and 108th AGM notice, with the AGM set for 30 November 2026. The filing is a Regulation 34 intimation with no transaction or financial event.

Annual ReportViksit Engineering Ltd VIKSHEN

Viksit Engineering Annual Report

Viksit Engineering filed its 44th Annual Report for FY 2025-26 with BSE. The report includes notice of the AGM on 30 November 2026.

Annual ReportInnovision Ltd INNOVISION

Innovision Annual Report

Innovision Ltd filed its FY2025-26 Annual Report with the notice of its 20th AGM, scheduled for 5 December 2026 via VC/OAVM. The notice covers financial statements, a director re-appointment and a non-executive director regularisation.